Evidence map›Paper›PMID 28223691›Full record

ArticleScientific reports2017

Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors.

Diluka Peiris, Alexander F Spector, Hannah Lomax-Browne, Tayebeh Azimi, Bala Ramesh, Marilena Loizidou, Hazel Welch, Miriam V Dwek

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 90 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Application of biosensors in cancers, an overview.Frontiers in bioengineering and biotechnology · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Displacement of Native FXYD Protein From NaFrontiers in oncology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Diluka PeirisAttana AB, Bjornnasvagen 21, SE-11419, Stockholm, Sweden.
Alexander F SpectorDivision of Surgery and Interventional Science, UCL Medical School Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK.
Hannah Lomax-BrowneDepartment of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, 115 New Cavendish St, W1W 6UW, UK.
Tayebeh AzimiDepartment of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, 115 New Cavendish St, W1W 6UW, UK.
Bala RameshDivision of Surgery and Interventional Science, UCL Medical School Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK.
Marilena LoizidouDivision of Surgery and Interventional Science, UCL Medical School Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK.
Hazel WelchDivision of Surgery and Interventional Science, UCL Medical School Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK.
Miriam V DwekDepartment of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, 115 New Cavendish St, W1W 6UW, UK.
University of Westminster · GBRoland Hill (United Kingdom) · GBUniversity College London · GBAttana (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in protein glycosylation are a key feature of oncogenesis and have been shown to affect cancer cell behaviour perturbing cell adhesion, favouring cell migration and metastasis. This study investigated the effect of N-linked glycosylation on the binding of Herceptin to HER2 protein in breast cancer and on the sensitivity of cancer cells to the chemotherapeutic agent doxorubicin (DXR) and growth factors (EGF and IGF-1). The interaction between Herceptin and recombinant HER2 protein and cancer cell surfaces (on-rate/off-rate) was assessed using a quartz crystal microbalance biosensor revealing an increase in the accessibility of HER2 to Herceptin following deglycosylation of cell membrane proteins (deglycosylated cells B

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell Line, TumorCell ProliferationConcanavalin ADoxorubicinDrug SynergismEpidermal Growth FactorErb-b2 Receptor Tyrosine KinasesFemaleGlycosylationHumansInsulin-Like Growth Factor IKineticsMicroscopy, FluorescenceProtein BindingAntineoplastic AgentsConcanavalin ADoxorubicinEpidermal Growth FactorErb-b2 Receptor Tyrosine KinasesInsulin-Like Growth Factor IRecombinant ProteinsTrastuzumabTunicamycin

Identifiers

PMID28223691
PMCPMC5320443
OpenAlexW2589185317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.